Genotypic and Phenotypic Evidence of Different Drug-Resistance Mutation Patterns between B and Non-B Subtype Isolates of Human Immunodeficiency Virus Type 1 found in Brazilian Patients Failing HAART

被引:0
作者
Elena Caride
Kurt Hertogs
Brendan Larder
Pascale Dehertogh
Rodrigo Brindeiro
Elizabeth Machado
Carlos A.M. De Sá
Walter A. Eyer-Silva
Fernando Samuel Sion
Luiz F.C. Passioni
Jaqueline A. Menezes
Alexandre R. Calazans
Amilcar Tanuri
机构
[1] UFRJ,Laboratory of Molecular Virology, Genetic Department
[2] VIRCO,Central Virological Laboratory
[3] Hospital dos Servidores do Estado,undefined
[4] Rio de Janeiro,undefined
[5] Brazil; Hospital Universitário Clementino Fraga Filho,undefined
来源
Virus Genes | 2001年 / 23卷
关键词
HIV-1; Protease; Phenotyping; Genotyping; Subtype;
D O I
暂无
中图分类号
学科分类号
摘要
We have investigated the phenotypic and genotypic susceptibility of 14 HIV-1 strains isolated from individuals failing HAART therapy to protease inhibitors (PI). Proviral and plasma viral pol gene fragment were amplified, sequenced and subtyped. Nine samples clustered with protease subtype B reference strains and the remaining samples were classified as non-B subtype corresponding to subtype F (n=4) and subtype A (n=1). Although all patients were treated with similar PI drug regimen, the non-B subtype isolates did not present the L90M and I84V mutations and used mainly G48V and V82A/F to achieve drug resistance. A strong cross-resistance phenotype among all four PI was associated with the mutation L90M in the subtype-B isolates, and with G48V and V82A/F in the non-B counterparts. This observation revealed that the non-B viruses tested had specific genotypic characteristics contrasting with the subtype-B isolates.
引用
收藏
页码:193 / 202
页数:9
相关论文
共 348 条
[1]  
Pillay D.(1995)HIV-1 protease inhibitors: Their development, mechanism of action and clinical potential Med Virol 5 23-33
[2]  
Bryant M.(1997)Human immunodeficiency virus type 1 protease inhibitors Arch Intern Med 157 951-959
[3]  
Getman D.(1995)A preliminary study of ritonavir an inhibitor of HIV-1 protease, to treat HIV-1 infection N Engl J Med 333 1534-1539
[4]  
Richman D.D.(1996)Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine N Engl J Med 334 1011-1017
[5]  
McDonald C.K.(1996)Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity Antiretrovial therapy for HIV infection JAMA 276 146-154
[6]  
Kuritzkes D.R.(1996)Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study Antiviral Res 29 91-93
[7]  
Markowitz M.(1999)Multiple concurrent reverse transcriptase and protease mutations multidrug resistance of HIV-1 isolates from heavily treated patients Lancet 353 863-868
[8]  
Saag M.(1998)Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Ann Intern Med 128 906-911
[9]  
Powderly W.G.(1997)Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy Science 278 1295-1300
[10]  
Hurley A.M.(1999)Development of drug resistance to HIV-1 protease inhibitors N Engl J Med 340 1605-1613